OPKO Health Files 13D/A Amendment for GeneDx Holdings

TL;DR

OPKO Health updated its 13D filing for GeneDx Holdings, watch for ownership changes.

AI Summary

OPKO Health, Inc. filed an amendment to its Schedule 13D on November 8, 2024, regarding its beneficial ownership of GeneDx Holdings Corp. The filing indicates a change in the reporting person's holdings, though specific new dollar amounts or percentages are not detailed in this excerpt. This amendment relates to the ongoing reporting requirements for significant shareholders.

Why It Matters

This filing is important for investors tracking significant ownership changes in GeneDx Holdings Corp., as it signals potential shifts in control or influence by major shareholders like OPKO Health.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings can indicate significant changes in a company's ownership structure, potentially impacting stock price and corporate strategy.

Key Players & Entities

• OPKO HEALTH, INC. (company) — Filing entity
• GeneDx Holdings Corp. (company) — Subject company
• Sema4 Holdings Corp. (company) — Former name of GeneDx Holdings Corp.
• CM Life Sciences, Inc. (company) — Former name of GeneDx Holdings Corp.

FAQ

Key Financial Figures

• $0.0001 — suer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $74.90 — the open market at prices ranging from $74.90 to $80.00 per share for an aggregate sa
• $80.00 — market at prices ranging from $74.90 to $80.00 per share for an aggregate sale price o
• $32,850,791 — n aggregate sale price of approximately $32,850,791. ITEM 5. Interest in Securities of
• $33.00 — the open market at prices ranging from $33.00 to $80.00 per share for an aggregate sa
• $44,176,226 — n aggregate sale price of approximately $44,176,226. Sales of GeneDx Common Stock prior to

Filing Documents

• opk20241107_sc13da.htm (SC 13D/A) — 63KB
• 0001437749-24-034241.txt ( ) — 65KB

is amended by adding the following paragraph to the end of the item

Item 4 is amended by adding the following paragraph to the end of the item: In a series of transactions between November 4, 2024 and November 8, 2024, OPKO sold a total of 310,000 shares of GeneDx Common Stock on the open market at prices ranging from $74.90 to $80.00 per share for an aggregate sale price of approximately $32,850,791. ITEM 5. Interest in Securities of the Issuer.

is deleted in its entirety and replaced with the following text

Item 5 is deleted in its entirety and replaced with the following text: (a) The Company's beneficial ownership of GeneDx Common Stock is as set forth in the table below: Name and Title of Beneficial Owner Number of Outstanding Shares Beneficially Owned Percentage of Outstanding Common Shares (1) OPKO Health, Inc. 1,746,674 6.36% ______________ (1) Based on 27,471,397shares of GeneDx Common Stock of the Issuer outstanding on October 22, 2024, as set forth in the Issuer's Form 10-Q filed with the SEC on October 29, 2024. (b) Items 7-10, inclusive, set forth on the cover page to this Amendment are hereby incorporated by reference in this Item 5. (c) In the last 60 days prior to the filing of this Amendment No. 8, OPKO sold a total of 618,666 shares of GeneDx Common Stock on the open market at prices ranging from $33.00 to $80.00 per share for an aggregate sale price of approximately $44,176,226. Sales of GeneDx Common Stock prior to September 18, 2024 were previously reported in Amendment No. 4, Amendment No. 5, Amendment No. 6, and Amendment No. 7. The following table sets forth the information with regard to GeneDx Common Stock sold by OPKO on the open market in the last 60 days. Date Shares of Common Stock Aggregate Sale Price Weighted Price Per Share 9/9/24 50,000 $ 1,668,268 $ 33.3654 9/11/24 50,000 $ 1,743,314 $ 34.8663 9/12/24 100,000 $ 3,828,812 $ 38.2881 9/13/24 8,666 $ 331,804 $ 38.2881 9/16/24 50,000 $ 1,878,759 $ 37.5752 9/17/24 50,000 $ 1,874,478 $ 37.4896 11/4/24 25,000 $ 1,902,415 $ 76.0966 11/5/24 75,000 $ 5,699,171 $ 75,9889 11/6/24 150,000 $ 11,510,776 $ 76.7385 11/7/24 50,000 $ 3,861,068 $ 77.2214 11/8/24 10,000 $ 9,877,361 $ 79.0189 CUSIP No. 81663L200 Schedule 13D PAGE 4 of 5 (d) Except as described herein, no other person is known by OPKO to have the right to receive or the power to direct the receipt of div

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. OPKO Health, Inc. Dated: November 8, 2024 By: /s/ Steven D. Rubin Name: Steven D. Rubin Title: Executive Vice President - Administration

View Full Filing

View this SC 13D/A filing on SEC EDGAR